PROSPECTUS SUPPLEMENT (to the Prospectus dated February 11, 2021)Prospectus Supplement • October 26th, 2021
We have previously entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc., or B. Riley, relating to the offer and sale of shares of our Common Stock, par value $0.0001 per share, offered by this prospectus supplement through or to B. Riley as our agent or principal. In accordance with the terms of the Sales Agreement, under this prospectus supplement we may offer and sell shares of our Common Stock having an aggregate offering price of up to $48,537,500.
PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020)Prospectus Supplement • September 25th, 2020 • New York
This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $300,000,000. This prospectus provides you with a general description of the securities we may offer.
PROSPECTUS SUPPLEMENTProspectus Supplement • May 25th, 2022
process. Under the shelf registration process, the Fund may offer, from time to time, in one or more offerings, Common Shares on terms to be determined at the time of the offering. This prospectus provides you with a general description of the Common Shares that the Fund may offer. Each time the Fund uses this prospectus to offer Common Shares, the Fund will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement, which contain important information about the Fund, carefully before you invest in the Common Shares. Common Shares may be offered directly to one or more purchasers, through agents designated from time to time by the Fund, or to or through underwriters or dealers. The prospectus supplement relating to an offering will identify any agents, underwriters or dea
Virgin Galactic Holdings, Inc.Prospectus Supplement • September 20th, 2022
We have entered into a distribution agency agreement (the “Distribution Agency Agreement”) with Credit Suisse Securities (USA) LLC (“Credit Suisse”), Morgan Stanley & Co. LLC (“Morgan Stanley”) and Goldman Sachs & Co. LLC (collectively with Credit Suisse and Morgan Stanley, the “Agents”), dated August 4, 2022, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Distribution Agency Agreement, we may offer and sell shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $300,000,000 from time to time through or to the Agents, acting as our agents or as principal.
PROSPECTUS SUPPLEMENTProspectus Supplement • September 30th, 2020
DoubleLine Opportunistic Credit Fund (the “Fund”) has entered into a distribution agreement dated September 30, 2020 (the “Distribution Agreement”) with Foreside Fund Services, LLC (the “Distributor”), relating to the Fund’s common shares of beneficial interest, par value $0.00001 per share (“Common Shares”), offered by this Prospectus Supplement and the accompanying Prospectus. The Distributor has entered into a sub-placement agent agreement dated September 30, 2020 (the “Sub-Placement Agent Agreement” and, together with the Distribution Agreement, the “Sales Agreements”) with UBS Securities LLC (the “Sub-Placement Agent” and, together with the Distributor, the “Sales Agents”), relating to the Common Shares offered by this Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sub-Placement Agent Agreement, the Fund may offer up to $100,000,000 Common Shares, par value $0.00001 per share, from time to time through the Sub-Placement Agent, as its age
CREDIT SUISSE HIGH YIELD BOND FUNDProspectus Supplement • April 16th, 2015
Credit Suisse High Yield Bond Fund (the “Fund”) has entered into an amended and restated sales agreement (the “sales agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) relating to its common shares of beneficial interest (“Common Shares”) offered by this Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the sales agreement, the Fund may offer and sell up to 18,000,000 of its Common Shares, par value $0.001 per share, from time to time through JonesTrading as its agent for the offer and sale of the Common Shares, subject to an aggregate cap under the Fund’s shelf registration statement (the “Shelf”) of $67,915,137, which amount reflects the issuance of $25,863,264 of proceeds from the issuance of Common Shares under the Shelf as of March 31, 2015. As of March 31, 2015, the Fund had offered and sold 23,824,249 Common Shares pursuant to the sales agreement and prior sales agreements with JonesTrading. As of March 31, 2015, there
TransEnterix, Inc.Prospectus Supplement • March 11th, 2018
We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or the Agent, to offer and sell up to $25,000,000 from time to time of shares of our common stock, $0.001 par value per share, under this prospectus supplement and the accompanying prospectus dated December 19, 2014.
We have entered into an At Market Issuance Sales Agreement, dated April 3, 2019, as amended on April 23, 2020, or the sales agreement, with B. Riley FBR, Inc., or B. Riley FBR, pursuant to which we may offer and sell shares of our common stock from...Prospectus Supplement • July 27th, 2020 • New York
The items in the following summary are described in more detail elsewhere in this prospectus and in the documents incorporated by reference herein. This summary provides an overview of selected information and does not contain all the information you should consider before investing in our securities. Therefore, you should carefully read the entire prospectus, any prospectus supplement and any free writing prospectus that we have authorized for use in connection with this offering, including the “Risk Factors” section and other documents or information included or incorporated by reference in this prospectus and any prospectus supplement before making any investment decision.
PROSPECTUS SUPPLEMENTProspectus Supplement • September 4th, 2020
We are a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, we have established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor, and on improving in vitro fertilization outcomes. We have assembled a strong management team with extensive experience in successfully developing and commercializing therapeutics in our target market. Our goal is to build the leading women’s reproductive health and pregnancy company focused on conditions where current treatment options are limited and significant unmet needs exist.
LUMINAR TECHNOLOGIES, INC. STRATEGIC CAPITAL FINANCE PROGRAMProspectus Supplement • March 1st, 2023
Our vision is to make autonomous transportation safe and ubiquitous. As a global leader in lidar autonomous driving technology, we are enabling the world’s first autonomous solutions for automotive series production in passenger cars and commercial trucks.
PROSPECTUS SUPPLEMENTProspectus Supplement • February 15th, 2023
This summary highlights selected information that is presented in greater detail elsewhere, or incorporated by reference, in this prospectus. It does not contain all of the information that may be important to you and your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including the matters set forth under the section of this prospectus captioned “Risk Factors” and the financial statements and related notes and other information that we incorporate by reference herein, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-
Tortoise Energy Infrastructure Corporation Common StockProspectus Supplement • July 3rd, 2021
The following summary contains basic information about us and our securities. It is not complete and may not contain all of the information you may want to consider before investing in our securities. You should review the more detailed information contained in this prospectus and in any related prospectus supplement and in the statement of additional information, especially the information set forth under the heading “Risk Factors” beginning on page 39 of this prospectus.
Common StockProspectus Supplement • April 20th, 2022
In accordance with the terms of the Capital on DemandTM Sales Agreement entered into with JonesTrading Institutional Services LLC (“JonesTrading” or the “Agent”), dated April 20, 2022, which we refer to as the Sales Agreement, we may offer and sell under this prospectus supplement and accompanying prospectus shares of our Common Stock, $0.001 par value per share, having an aggregate offering price of up to $4,870,000 from time to time through or to the Agent, acting as sales agent or principal.
We have entered into an At Market Issuance Sales Agreement, or sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated August 13, 2020, relating to the sale of shares of our common stock offered by this prospectus supplement. In...Prospectus Supplement • August 13th, 2020
This prospectus supplement relates to the offering of our common stock. Before buying any of the common stock that we are offering, you should carefully read the accompanying base prospectus, this prospectus supplement, any supplement to this prospectus supplement, the information and documents incorporated herein by reference and the additional information under the heading “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference.” These documents contain important information that you should consider when making your investment decision.
Through September 11, 2013, we had issued and sold 3,772,254 common shares under the distribution agency agreement and had receivedProspectus Supplement • January 28th, 2017
This prospectus supplement should be read in conjunction with, and may not be delivered or utilized without, the prospectus dated August 13,
CANCER GENETICS, INC.Prospectus Supplement • July 16th, 2015
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a "shelf" registration process. Under this shelf process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $100,000,000. We have provided to you in this prospectus a general description of the securities we may offer. Each time we sell securities under this shelf registration process, we will provide a prospectus supplement that will contain specific information about the terms of the offering. We may also add, update or change in the prospectus supplement or any "free writing prospectus" we may authorize to be delivered to you any of the information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement or any free writing prospectus we may authorize to be delivered to you, you should re
Maximum of 20,000,000 SharesProspectus Supplement • March 31st, 2020 • New York
This prospectus is part of a registration statement on Form S-3 that we filed with the SEC, using a “shelf” registration process for the delayed offering and sale of securities pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”). Under the shelf registration process, we may, over time, sell any combination of the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities that we may offer. As allowed by SEC rules, this prospectus does not contain all of the information that you can find in the registration statement or the exhibits thereto. For further information, we refer you to the registration statement, including any amendments thereto, including its exhibits.
Up to $150,000,000Prospectus Supplement • August 24th, 2022 • New York
This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the sections titled “Risk Factors” contained in this prospectus, the applicable prospectus supplement and any related free writing prospectus, and under similar sections in the other documents that are incorporated by reference into this prospectus. You should also carefully read the other information incorporated by reference into this prospectus, including our consolidated and condensed consolidated financial statements, and the exhibits to the registration statement of which this prospectus is a part.
Up to $50,000,000Prospectus Supplement • September 22nd, 2020 • New York
This prospectus is part of a “shelf” registration statement that we have filed with the SEC. By using a shelf registration statement, we may sell, at any time and from time to time, in one or more offerings, any combination of the securities described in this prospectus. The exhibits to our registration statement and documents incorporated by reference contain the full text of certain contracts and other important documents that we have summarized in this prospectus or that we may summarize in a prospectus supplement. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents. The registration statement and the exhibits and other documents can be obtained from the SEC as indicated under the sections entitled “Where You Can Find More Information” and “Incorporation by Reference of Information Filed with the SEC.”
Up to $200,000,000Prospectus Supplement • February 25th, 2022 • New York
We have entered into an At-The-Market Issuance Sales Agreement, or the sales agreement, with Ascendiant Capital Markets, LLC, or ACM, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $200,000,000 from time to time through ACM, acting as sales agent, at our discretion.
American Depositary Shares representing Ordinary SharesProspectus Supplement • October 20th, 2022
We are a biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have extensive experience in research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. We have built, internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise, and we have received upfront and milestone payments and equity investments. We believe our product ca
PROSPECTUS SUPPLEMENT (To Prospectus dated March 19, 2020)Prospectus Supplement • July 29th, 2020 • Delaware
On June 17, 2020, we entered into an equity distribution agreement, or the equity distribution agreement, with UBS Securities LLC, or the sales agent, relating to the sale of shares of our common stock with an aggregate gross sales price of up to $45,000,000. On June 17, 2020, pursuant to the equity distribution agreement, we filed a prospectus supplement pursuant to which we could offer and sell from time to time shares of our common stock having an aggregate gross sales price of up to $45,000,000 through the sales agent. On July 29, 2020 we entered into amendment no. 1 to the equity distribution agreement, or amendment no. 1, increasing the aggregate gross sales price by an additional $27,000,000 offered by this prospectus supplement. In accordance with the terms of the equity distribution agreement, as amended by amendment no. 1, we may offer and sell shares of our common stock pursuant to this prospectus supplement having an aggregate offering price of up to $27,000,000 from time t
READY CAPITAL CORPORATIONProspectus Supplement • January 28th, 2022
This prospectus is part of a shelf registration statement. Under this shelf registration statement, we may sell any combination of common stock, preferred stock, depositary shares, debt securities, warrants, and rights. You should rely only on the information provided or incorporated by reference in this prospectus or any applicable prospectus supplement. We have not authorized anyone to provide you with different or additional information. We are not making an offer to sell these securities in any jurisdiction where the offer or sale of these securities is not permitted. You should not assume that the information appearing in this prospectus or any applicable prospectus supplement or the documents incorporated by reference herein or therein is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read carefully the entirety of this prospectus and any applicable pr
Up to $25,000,000Prospectus Supplement • May 24th, 2022
Our mission is to re-humanize healthcare by enabling doctors to practice medicine that is centered on patients. Our solution helps relieve the burden of medical note documentation so that doctors can focus on what they do best — patient care.
We have entered into an At-the-Market Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or Virtu, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying...Prospectus Supplement • May 27th, 2020
This prospectus is part of a registration statement we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf registration process, we may, from time to time, offer and sell any combination of the securities described in this prospectus in one or more offerings. The aggregate initial offering price of all securities sold under this prospectus will not exceed $100,000,000.
Up to $75,000,000Prospectus Supplement • February 26th, 2020
We have entered into an open market sales agreement, or a sales agreement, with Jefferies LLC, or the Agent, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, $0.00001 par value per share, having an aggregate offering price of up to $75,000,000 from time to time through the Agent acting as our agent.
TeraWulf Inc.Prospectus Supplement • May 14th, 2022 • New York
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), using a “shelf” registration process. Under this shelf registration process, we may offer and sell from time to time shares of our common stock, shares of our preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts or units, or any combination thereof, in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering, with an aggregate initial offering price of up to $500,000,000 (or its equivalent in foreign currencies, currency units or composite currencies). This prospectus provides you with a general description of the securities. Each time we offer the securities, we will provide a prospectus supplement that describes the terms of the offering. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you shou
Up to $625,000,000Prospectus Supplement • April 28th, 2023
We have entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC and Canaccord Genuity LLC (collectively, the “Agents”), dated May 1, 2023, relating to the sale of shares of our class A common stock, par value $0.001 per share, offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, under this prospectus supplement, we may offer and sell shares of our class A common stock having an aggregate offering price of up to $625,000,000 from time to time through one or more of the Agents, acting as our sales agents.
PROSPECTUS SUPPLEMENTProspectus Supplement • January 19th, 2024 • New York
We have entered into an At Market Issuance Sales Agreement (the “sales agreement”) with B. Riley Securities, Inc. (“B. Riley Securities”) relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. We may offer and sell shares of our common stock having an aggregate offering price of up to $1,000,000,000, from time to time through or to B. Riley Securities as sales agent or principal.
Up to $14,999,425Prospectus Supplement • October 4th, 2022 • New York
We have entered into an Equity Distribution Agreement, or the Distribution Agreement, with Canaccord Genuity LLC, or Canaccord, acting as sales agent, on October 3, 2022, relating to the sale of shares of our Class A common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Distribution Agreement, under this prospectus supplement, we may offer and sell shares of our Class A common stock having an aggregate offering price of up to $14,999,425 from time to time through Canaccord.
Common StockProspectus Supplement • September 1st, 2022
We have entered into a Sales Agreement (Sales Agreement) with Cowen and Company, LLC (Cowen) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, under this prospectus supplement, we may offer and sell shares of our common stock having an aggregate offering price of up to $125,000,000 from time to time through or to Cowen, acting as our agent.
Up to US$50,000,000Prospectus Supplement • February 14th, 2022
We have entered into a sales agreement, or Sales Agreement, with Evercore Group L.L.C., or Evercore, dated May 5, 2020, relating to the sale of our common shares from time to time offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell our common shares having an aggregate offering price of up to US$50,000,000 from time to time through Evercore, acting as our sales agent.
Up to $10,000,000 Common StockProspectus Supplement • May 17th, 2022
This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” and “would,” or the negative of these terms, or similar expressions. Such forward-looking statements are subject to certain risks, uncertainties and assumptions relating to factors that could cause actual results to differ materially from those anticipated in such statements, including, without limitation, the f
PROSPECTUS SUPPLEMENTProspectus Supplement • April 30th, 2019 • Delaware
This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we have filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may offer any combination of our securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $180,000,000. The $50,000,000 of common stock that may be offered, issued and sold under this prospectus supplement is included in the $180,000,000 of securities that may be offered, issued and sold by us pursuant to our shelf registration statement.
Up to [—] Shares Common StockProspectus Supplement • March 21st, 2014 • Hercules Technology Growth Capital Inc
We have entered into an equity distribution agreement, dated [—], 2014, with [—], relating to the shares of common stock offered by this prospectus supplement and the accompanying prospectus. Our common stock is listed on the New York Stock Exchange, or NYSE, under the trading symbol “HTGC.” The last sale price, as reported on NYSE on [—], 2014, was $[—] per share. The net asset value per share of our common stock at [—], 2014 (the last date prior to the date of this prospectus supplement on which we determined net asset value) was $[—].
